SEC Form 4 · accession 0001209191-17-024291
Atara Biotherapeutics, Inc. · ATRA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Joe Newell
Officer — Chief Tech. Operations Officer
Period of report
Apr 3, 2017
Accepted (ET)
Apr 3, 2017 · 7:34 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001604464
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Apr 3, 2017 | A | 7,500 | $0.00 | A | 7,500 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (Right to Buy)F2 | $20.40 | Apr 3, 2017 | A | 90,000 | A | — | Apr 3, 2024 | Common Stock | 90,000 | 90,000 | D |
Explanation of responses
- F1These restricted stock units vest in four equal annual installments on each of the first, second, third and fourth anniversaries from April 3, 2017, subject to the reporting person's continuous service.
- F225% of the shares shall vest one year from April 3, 2017, and the remaining shares shall vest in 36 equal monthly installment thereafter, subject to the reporting person's continuous service.